Interim 24-month data from Tigris, SpyGlass Pharma’s first-in-human trial for the bimatoprost drug pad-intraocular lens system (BIM-IOL System) demonstrated sustained improvements in intraocular pressure and visual acuity outcomes, the company announced. The BIM-IOL, comprised of novel, proprietary nonbioerodible drug pads attached to SpyGlass Pharma’s IOL, is designed to be implanted during routine cataract surgery to reduce IOP in patients with primary open-angle glaucoma or ocular hypertension by consistently delivering multiple years of bimatoprost, a prostaglandin analog.

At 24 months, SpyGlass Pharma reported that the BIM-IOL system produced a 42% reduction in mean IOP, decreasing from 25.1±2.5 mmHg at baseline after washout to 14.5±3.0 mmHg (P<.0001), with no statistically significant difference in IOP reduction across the 3 dosage groups tested. All patients were able to discontinue topical IOP-lowering medications, and best-corrected distance visual acuity improved to 20/30 or better in every patient.

Additionally, SpyGlass said the BIM-IOL system was observed to be well tolerated. Any adverse events were considered to be related to the cataract procedure and not associated with the BIM-IOL system; no serious adverse events were observed. GP